Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PLUR
PLUR logo

PLUR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Pluri Inc (PLUR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.480
1 Day change
52 Week Range
6.100
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Pluri Inc (PLUR) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. Despite slight revenue growth and improvement in net income, the company is still operating at a significant loss. Technical indicators are neutral, and there are no strong trading signals or catalysts to suggest immediate upside potential. Holding off on investment until stronger signals or catalysts emerge is advisable.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 52.124, and moving averages are converging, indicating no clear trend. Key support and resistance levels suggest limited price movement in the short term.

Positive Catalysts

  • Revenue increased by 7.03% YoY, and net income improved significantly by 121.35% YoY, though still negative.

Neutral/Negative Catalysts

  • No recent news or significant insider/hedge fund activity to drive sentiment.

Financial Performance

In Q2 2026, revenue increased to $198,000 (+7.03% YoY), net income improved to -$6,543,000 (+121.35% YoY), and EPS rose to -0.71 (+33.96% YoY). However, gross margin dropped to 43.43% (-27.62% YoY), indicating potential cost pressures.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast PLUR stock price to rise
Analyst Rating
0
Wall Street analysts forecast PLUR stock price to rise
Buy
Hold
Sell
0
Current: 3.485
sliders
Low
0
Averages
0
High
0
0
Current: 3.485
sliders
Low
0
Averages
0
High
0
Alliance Global Partners
Matthew Venezia
initiated
$12
AI Analysis
2025-06-02
Reason
Alliance Global Partners
Matthew Venezia
Price Target
$12
AI Analysis
2025-06-02
initiated
Reason
Alliance Global Partners analyst Matthew Venezia re-initiated coverage of Pluri with a Buy rating and $12 price target. The company has transitioned from a clinical-stage cell therapy biotech with some novel bioreactor technology to a diversified biotech applying its "differentiated" bioreactor technology in multiple fields, the analyst tells investors in a research note. The firm says Pluri's bioreactor system which solves many issues with current bioreactors related to scale up and production of cell-based products.

People Also Watch